COVID-19 infection and vaccination against COVID-19: Impact on managing demyelinating CNS disorders in Southern India- experience from a demyelinating disease registry.

Pandit, Lekha; Akshatha, S; Malli, Chaithra; D’Cunha, Anitha

doi:10.1016/j.msard.2022.104033

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the development of vaccines against COVID-19 has markedly reduced hospitalisations for the general public, 7 the risk of COVID-19 infection and severe outcomes in pwMS with attenuated vaccine responses is not yet fully understood. Some authors have demonstrated that COVID-19 vaccination reduces infection risk in all pwMS regardless of DMT exposure, 3,8,9 while others suggest that people taking anti-CD20 and S1P modulating drugs do not derive as much benefit from COVID vaccines at a population level. 10 However, these studies did not measure serology in all participants, instead focussing on clinical infection.…”

Section: Introductionmentioning

confidence: 99%

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

Zaloum,

Wood,

Tank

et al. 2023

Mult Scler

View full text Add to dashboard Cite

Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear. Objective: To report COVID-19 rates in pwMS according to vaccine serology. Methods: PwMS with available (1) serology 2–12 weeks following COVID-19 vaccine 2 and/or vaccine 3 and (2) clinical data on COVID-19 infection/hospitalisation were included. Logistic regression was performed to examine whether seroconversion following vaccination predicted risk of subsequent COVID-19 infection after adjusting for potential confounders. Rates of severe COVID-19 (requiring hospitalisation) were also calculated. Results: A total of 647 pwMS were included (mean age 48 years, 500 (77%) female, median Expanded Disability Status Scale (EDSS) 3.5% and 524 (81%) exposed to DMT at the time of vaccine 1). Overall, 472 out of 588 (73%) were seropositive after vaccines 1 and 2 and 222 out of 305 (73%) after vaccine 3. Seronegative status after vaccine 2 was associated with significantly higher odds of subsequent COVID-19 infection (odds ratio (OR): 2.35, 95% confidence interval (CI): 1.34–4.12, p = 0.0029), whereas seronegative status after vaccine 3 was not (OR: 1.05, 95% CI: 0.57–1.91). Five people (0.8%) experienced severe COVID-19, all of whom were seronegative after most recent vaccination. Conclusion: Attenuated humoral response to initial COVID-19 vaccination predicts increased risk of COVID-19 in pwMS, but overall low rates of severe COVID-19 were seen.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

Zaloum,

Wood,

Tank

et al. 2023

Mult Scler

View full text Add to dashboard Cite

show abstract

Global trends in research on MOG antibody-associated disease: bibliometrics and visualization analysis

Zheng,

Wang,

Geng

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectiveThe purpose of this study was to investigate the current research status, focus areas, and developmental trends in the field of Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) through an analysis of scientific literature.MethodsThe relevant research articles on MOGAD published from 1947 to 2022 were retrieved from the Web of Science database. The quantitative output of MOGAD related research articles, their distribution by country/region, data on collaborative publishing, influential authors, high-yield institutions, keywords, hotspots, and development trends were analyzed. Additionally, visual knowledge maps were generated using VOSviewer and Citespace.ResultsThere has been a steady increase in the number of MOGAD related publications indicating that the subject has garnered increasing interest among researchers globally. The United States has been the leading contributor with 496 papers (19.25%), followed by China (244, 9.63%), Japan (183, 7.10%), the United Kingdom (154, 5.98%), and Germany (149, 5.78%). Among these countries, the United Kingdom boasts the highest citation frequency at the rate of 46.49 times per paper. Furthermore, active collaboration in MOGAD related research is observed primarily between the United States and countries such as Canada, Germany, Australia, Italy, the United Kingdom and Japan. Mayo Clinic ranks first in total articles published (109) and frequency of citations per article (77.79). Takahashi Toshiyuki from Tohoku University is the most prolific author, while Multiple Sclerosis and Related Disorders is the most widely read journal in this field. “Disease Phenotype”, “Treatment”, “Novel Coronavirus Infection and Vaccination”, “Immunopathological Mechanisms”, “Clinical characteristics of children” and “Prognosis” are the primary keywords clusters in this field. “Novel Coronavirus Infection and Vaccination” and “Immunopathological Mechanisms” are research hotspots and have great development potential.ConclusionThe past three decades have witnessed a significant expansion of research on MOGAD. The pathogenetic mechanism of MOGAD is poised to be the prominent research focus in this field in the foreseeable future.

show abstract

COVID-19 infection and vaccination against COVID-19: Impact on managing demyelinating CNS disorders in Southern India- experience from a demyelinating disease registry.

Cited by 2 publications

References 27 publications

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

Global trends in research on MOG antibody-associated disease: bibliometrics and visualization analysis

Contact Info

Product

Resources

About